Stocktoria
Contineum Therapeutics, Inc. CTNM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-04-05
Chart by TradingView
2/9
Piotroski F — financial health
19.89
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Revenue | — | $0 | $50.0M |
| Operating income | -$68.1M | -$50.9M | $16.1M |
| Net income | -$60.0M | -$42.3M | $22.7M |
| Operating cash flow | -$55.3M | -$32.8M | $19.3M |
| Free cash flow | -$55.5M | -$33.4M | $18.9M |
| Total assets | $276.6M | $212.8M | $130.4M |
| Total liabilities | $15.7M | $14.8M | $5.7M |
| Shareholders' equity | $261.0M | $198.1M | -$67.9M |
| Ratios | |||
| Operating margin | — | — | 32.2% |
| Net margin | — | — | 45.4% |
| FCF margin | — | — | 37.9% |
| Return on assets | -21.7% | -19.9% | 17.4% |
| Return on equity | -23.0% | -21.3% | -33.4% |
| Current ratio | 27.50 | 20.69 | 23.29 |
| Revenue growth | — | -100.0% | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 84,891 | $1.1M |
| RENAISSANCE TECHNOLOGIES LLC | 69,400 | $906,364 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 19.89 (safe)
- Working capital / assets 0.933
- Retained earnings / assets -0.641
- EBIT / assets -0.246
- Equity / liabilities 16.673
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001855175 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.